Thibault Mesplèdes

23PUBLICATIONS
49CO-AUTHORS
PharmacogenomicsRegenerative medicine (incl. stem cells)Major global burdens of diseaseDisease surveillanceInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Feb 04, 2026
Cooperation between HIV-1 integrase natural polymorphism K156N and 3'PPT mutations in dolutegravir monotherapy failure.

Jolieke A T van Osch, Jolanda J C Voermans, Haajar Ouzerne

|Jul 30, 2025
Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions.

Anna Maria Geretti, Marta Boffito, Stefano Bonora

|Jul 07, 2025
How frequent is dolutegravir resistance?

Jolieke A T van Osch, Thibault Mesplède

|Jul 02, 2025
Insights to a Cure: Unique Controller Phenotypes in the Rotterdam HIV-2 Cohort.

Kathryn S Hensley, Rob A Gruters, Els van Nood

|Mar 26, 2025
Computational and Population-Based HLA Permissiveness to HIV Drug Resistance-Associated Mutations.

Rizwan Mahmud, Zoë Krullaars, Jolieke van Osch

|Jan 01, 2025
Novel Dolutegravir and Lenacapavir Resistance Patterns in Human Immunodeficiency Virus Type 2 Infection: A Case Report.

Jeroen J A van Kampen, Els van Nood, Rizwan Mahmud

Pageof 4